We are a clinical-stage biopharmaceutical company focused on bringing unconventional scientific innovations to patients whose lives remain burdened by their disease. We draw upon our deep knowledge and experience in drug development across multiple therapeutic areas as we build a unique, diversified, multi-asset portfolio of therapies in inflammation and immunology that target select pathways in specific tissues, with our initial focus on one of the most important ‘immune’ tissues, the skin. Utilizing our novel technology platform, we apply a scientific design process to create potent targeted pharmacologically active molecules that are directed toward a specific target tissue and a select disease pathway, and with minimal to no systemic exposure. Our lead candidate from this platform,SNA-120 (pegcantratinib), is afirst-in-class inhibitor of Tropomyosin receptor kinase A (TrkA) for which we intend to initiate two Phase 3 pivotal clinical trials for the treatment of psoriasis, as well as the associated pruritus (itch), subject to securing sufficient capital to complete both trials. Our second product candidate,SNA-125, is a dual Janus kinase 3 (JAK3)/TrkA inhibitor for which we intend to initiate Phase 2 clinical trials for the treatment of atopic dermatitis, psoriasis and the associated pruritus, subject to securing sufficient capital. Additionally,SNA-001, a silver photoparticle technology derived from our Topical Photoparticle Therapy™ platform to be used in conjunction with commonly used commercial lasers, recently completed the last of six pivotal clinical trials for the reduction of unwanted light-pigmented hair and for the treatment of acne. We are seeking a strategic partner to maximize the value ofSNA-001. We believe our management team is well-positioned to execute on our objectives, having served in clinical, commercial and other leadership roles at several marquee biotechnology and pharmaceutical companies including Kythera, Amgen, Allergan, Medicis, and Celgene. There is a significant opportunity to address the historical lack of innovation for treating inflammatory skin disorders in a targeted fashion without systemic exposure. Recent advances in biotechnology have enabled the development of novel, biologic drugs which act on specific molecular targets and pathways, and have been utilized to address inflammatory disorders. However, despite having shown impressive efficacy, use of these drugs has been limited to patients with more severe forms of disease due to the potentially significant side effects associated with systemic administration and their relatively high cost. Accordingly, the80-90% of patients with inflammatory skin disease who present withmild-to-moderate disease severity or more localized disease have not benefitted from these advances. Today, such patients typically resort tonon-specific, topical therapies such as corticosteroids and emollients, which are either marginally effective or unsuitable for chronic administration due to their side effects. We are initially focused on filling this innovation gap in inflammatory diseases of the skin by developing targeted products with minimal to no systemic exposure that are suitable for chronic administration.
Company profile
Ticker
SNNAQ
Exchange
Website
CEO
Frederick C. Beddingfield
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Sienna Labs, Inc.
SEC CIK
Corporate docs
SNNAQ stock data
Latest filings (excl ownership)
25-NSE
Exchange delisting
5 Feb 20
EFFECT
Notice of effectiveness
17 Dec 19
15-12B
Securities registration termination
11 Dec 19
POS AM
Prospectus update (post-effective amendment)
11 Dec 19
S-8 POS
Registration of securities for employees (post-effective amendment)
11 Dec 19
S-8 POS
Registration of securities for employees (post-effective amendment)
11 Dec 19
S-8 POS
Registration of securities for employees (post-effective amendment)
11 Dec 19
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
11 Dec 19
8-K
Sienna Biopharmaceuticals Announces Successful Appeal of Nasdaq Delisting Notice
15 Nov 19
10-Q
2019 Q3
Quarterly report
12 Nov 19
Latest ownership filings
SC 13G/A
Sienna Biopharmaceuticals, Inc.
14 Feb 20
SC 13G/A
Sienna Biopharmaceuticals, Inc.
7 Feb 20
4
Alexander Azoy
4 Oct 19
4
Timothy K. Andrews
8 Aug 19
4
Alexander Azoy
8 Aug 19
4
Paul F. Lizzul
8 Aug 19
4
III Frederick Beddingfield
8 Aug 19
4
Diane Stroehmann
3 Jul 19
4
Timothy K. Andrews
3 Jul 19
4
Paul F. Lizzul
3 Jul 19
Institutional ownership, Q3 2021
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 1 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|